StimOxyGen is an innovative biotech company focused on improving cancer treatment outcomes by tackling one of the field’s most critical challenges, tumour hypoxia. In many solid tumours, low oxygen levels significantly reduce the effectiveness of therapies such as radiotherapy and certain chemotherapies, creating a major barrier to successful treatment.
At the core of StimOxyGen’s approach is a proprietary, pH-responsive nanoparticle technology designed to generate oxygen directly within the tumour environment. These nanoparticles dissolve in low pH conditions and release controlled, transient bursts of oxygen, helping to restore the conditions needed for therapies to work effectively.
The company’s lead solution, SGEN-33, is engineered to precisely target hypoxic tumours and act as a radioenhancer, increasing the impact of radiotherapy while minimising damage to surrounding healthy tissue. By boosting oxygen levels at the point of treatment, StimOxyGen aims to significantly improve therapeutic response across a range of solid tumours.
Beyond radiotherapy, the platform has broader potential across oncology. The nanoparticles can carry additional therapeutic payloads and may be combined with emerging treatments such as immunotherapies, opening new pathways for more effective and integrated cancer care.
Built on more than 15 years of research into stimulus-responsive therapeutics, StimOxyGen is advancing its technology toward clinical development with a clear focus on improving patient outcomes and extending survival.
StimOxyGen’s mission is to transform cancer treatment by unlocking the full potential of existing therapies - delivering innovative solutions that overcome resistance and make treatments more effective for patients worldwide.
Visit website